Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.

Rudas, M; Lehnert, M; Huynh, A; Jakesz, R; Singer, C; Lax, S; Schippinger, W; Dietze, O; Greil, R; Stiglbauer, W; Kwasny, W; Grill, R; Stierer, M; Gnant, MF; Filipits, M; Clin Cancer Res. 2008; 14(6):176-174

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.

von Moos, R; Caspar, CB; Thürlimann, B; Angst, R; Inauen, R; Greil, R; Bergstrom, B; Schmieding, K; Pecherstorfer, M; Ann Oncol. 2008; 19(7):1266-1270

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Schmid, P; Kühnhardt, D; Kiewe, P; Lehenbauer-Dehm, S; Schippinger, W; Greil, R; Lange, W; Preiss, J; Niederle, N; Brossart, P; Freier, W; Kümmel, S; Van de Velde, H; Regierer, A; Possinger, K; Ann Oncol. 2008; 19(5):871-876

SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a.

Seyfried, I; Hofbauer, S; Stoecher, M; Greil, R; Tinhofer, I; Blood. 2008; 112(5):2168; author reply 2169

Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.

Merkel, O; Heyder, C; Asslaber, D; Hamacher, F; Tinhofer, I; Holler, C; Stöcher, M; Prokesch, A; Papak, C; Scheideler, M; Trajanoski, Z; Greil, R; J Mol Med (Berl). 2008; 86(5):541-552

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Gryshchenko, I; Hofbauer, S; Stoecher, M; Daniel, PT; Steurer, M; Gaiger, A; Eigenberger, K; Greil, R; Tinhofer, I; J Clin Oncol. 2008; 26(14): 2252-2257.

Erythropoietins in cancer patients: ESMO Recommendations for use

Greil, R; Thodtman, R; Roila, F ANN ONCOL. 2008; 19: 113-115.

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).

Mlineritsch, B; Tausch, C; Singer, C; Luschin-Ebengreuth, G; Jakesz, R; Ploner, F; Stierer, M; Melbinger, E; Menzel, C; Urbania, A; Fridrik, M; Steger, G; Wohlmuth, P; Gnant, M; Greil, R; BREAST CANCER RES TR. 2008; 112(1): 203-213.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

San Miguel, JF; Schlag, R; Khuageva, NK; Dimopoulos, MA; Shpilberg, O; Kropff, M; Spicka, I; Petrucci, MT; Palumbo, A; Samoilova, OS; Dmoszynska, A; Abdulkadyrov, KM; Schots, R; Jiang, B; Mateos, MV; Anderson, KC; Esseltine, DL; Liu, K; Cakana, A; van de Velde, H; Richardson, PG; N Engl J Med. 2008; 359(9):906-917

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

Arkenau, HT; Graeven, U; Kubicka, S; Grothey, A; Englisch-Fritz, C; Kretzschmar, A; Greil, R; Freier, W; Seufferlein, T; Hinke, A; Schmoll, HJ; Schmiegel, W; Porschen, R; CLIN COLORECTAL CANC. 2008; 7(1): 60-64.